ATS 2022

What biologic therapies effectively treat airway hyperresponsiveness in asthma, and what do these therapies show about the underlying biology of asthma?

TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.

Should enteral or IV vitamin C become standard of care in the treatment of patients with sepsis?

Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?

Can pulmonary rehabilitation improve outcomes in patients post-COVID-19 who are experiencing persistent and debilitating respiratory and other symptoms?

How do outcomes of endobronchial ultrasound-guided transbronchial fine needle aspiration differ in patients aged 65 or older vs those younger than 65?

Does omalizumab therapy for patients with moderate to severe allergic asthma affect these patients’ use of antitussives?

For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?

To what extent does depression influence asthma exacerbations? A population-based study presented at ATS 2022 examined the link between exacerbations and depression.

Is red blood cell distribution width a predictor of outcomes in patients with acute respiratory distress syndrome who are critically ill?